跳到主要导航 跳到搜索 跳到主要内容

Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model

  • Mingjie Dong
  • , Xianqiong Liu
  • , Katja Evert
  • , Kirsten Utpatel
  • , Michele Peters
  • , Shanshan Zhang
  • , Zhong Xu
  • , Li Che
  • , Antonio Cigliano
  • , Silvia Ribback
  • , Frank Dombrowski
  • , Antonio Cossu
  • , John Gordan
  • , Diego F. Calvisi
  • , Matthias Evert*
  • , Yan Liu*
  • , Xin Chen*
  • *此作品的通讯作者
  • Acad Mil Med Sci
  • Univ Calif San Francisco
  • Hubei Univ Chinese Med
  • Univ Regensburg
  • Ernst Moritz Arndt Univ Greifswald
  • Second Mil Med Univ
  • Azienda Osped Univ Sassari

科研成果: 期刊稿件 › 论文 › 同行评审

26 引用 (Scopus)

摘要

Intrahepatic cholangiocarcinoma (iCCA) is a deadly malignancy with limited treatment options. Gain-of-function mutations in K-Ras is a very frequent alteration, occurring in similar to 15 to 25% of human iCCA patients. Here, we established a new iCCA model by expressing activated forms of Notch1 (NICD) and K-Ras (K-Ras(V12D)) in the mouse liver (K-Ras/NICD mice). Furthermore, we investigated the therapeutic potential of MEK inhibitors in vitro and in vivo using human CCA cell lines and K-Ras/NICD mice, respectively. Treatment with U0126, PD901, and Selumetinib MEK inhibitors triggered growth restraint in all CCA cell lines tested, with the most pronounced growth suppressive effects being observed in K-Ras mutant cells. Growth inhibition was due to reduction in proliferation and massive apoptosis. Furthermore, treatment of K-Ras/NICD tumor-bearing mice with PD901 resulted in stable disease. At the molecular level, PD901 efficiently inhibited ERK activation in K-Ras/NICD tumor cells, mainly leading to increased apoptosis. Altogether, our study demonstrates that K-Ras/NICD mice represent a novel and useful preclinical model to study K-Ras-driven iCCA development and the effectiveness of MEK inhibitors in counteracting this process. Our data support the usefulness of MEK inhibitors for the treatment of human iCCA.
源语言英语
页数13
期刊CELL DEATH & DISEASE
卷9
DOI
出版状态已出版 - 18 1月 2018

基金资助

We like to thank Dr Allan Balmain of UCSF for providing LSL-K-RasG12D mice. This work is supported by NIH grants R01CA190606 to X.C.; and P30DK026743 for UCSF Liver Center; as well as grant from Cholangiocarcinoma Foundation to J.G.

联合国可持续发展目标

此成果有助于实现下列可持续发展目标:

  1. 可持续发展目标 3 - 良好健康与福祉
    可持续发展目标 3 良好健康与福祉

收录

  • SCIE

学术指纹

探究 'Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model' 的科研主题。它们共同构成独一无二的学术指纹。

引用此